Table 1.
Clinical trials involving leukemia and miRNAs as study parameters. The table includes 27 clinical trials conducted on patients with varying leukemia types that simultaneously either targeted or monitored miRNAs throughout the trial course, data acquired from the ClinicalTrials database.
| Study Start Year | Disease Type | Study Status | Study Approach | Therapeutic (If Any) | Age Group | Sample Source | Identifier |
|---|---|---|---|---|---|---|---|
| 2010 | Acute myeloid leukemia | Completed | Biomarker profiling | 0–1 | Tissue | NCT01229124 | |
| 2012 | B-cell acute lymphoblastic leukemia | Completed | Biomarker profiling | 15–65 | Tissue | NCT01505699 | |
| 2010 | Acute myeloid leukemia | Completed | Biomarker profiling | All | Tissue | NCT01057199 | |
| 2016 | Acute lymphoblastic leukemia | Unknown | Biomarker profiling | 2–19 | Blood | NCT03000335 | |
| 2012 | Acute myeloid leukemia | Completed | Biomarker profiling | 0–3 | Tissue, blood, bone marrow | NCT01511575 | |
| 2011 | Acute myeloid leukemia | Completed | Biomarker profiling | 0–30 | Bone marrow | NCT01298414 | |
| 2007 | Acute lymphoblastic leukemia | Unknown | Biomarker profiling | 1–18 | Not specified | NCT00526084 | |
| 2010 | Leukemia | Unknown | Biomarker profiling | 3–21 | Blood, cerebrospinal fluid | NCT01541800 | |
| 2009 | Acute myeloid leukemia | Active | Biomarker profiling | All | Blood, tissue | NCT00900224 | |
| 2009 | Acute myeloid leukemia | Active | Biomarker profiling | 15–59 | Blood, tissue | NCT00898092 | |
| 2011 | TEL/AML1-positive acute lymphoblastic leukemia | Completed | Expression study | 1–18 | Bone marrow | NCT01282593 | |
| 2012 | Acute myeloid leukemia | Completed | Treatment and expression study | Trebananib, low-dose cytarabine | 18+ | Blood, bone marrow | NCT01555268 |
| 2008 | Acute myeloid leukemia | Completed | Treatment and expression study | Azacitidine, bortezomib | 18+ | Blood, bone marrow | NCT00624936 |
| 2008 | Chronic myelomonocytic leukemia | Terminated | Treatment and expression study | Clofarabine | 18+ | Blood, bone marrow | NCT00708721 |
| 2016 | Acute myeloid leukemia | Not yet recruiting | Treatment and expression study | Decitabine | 65+ | Blood, bone marrow | NCT02698124 |
| 2009 | Acute lymphoblastic leukemia | Completed | Biomarker profiling | 1–21 | Blood, bone marrow | NCT00896766 | |
| 2010 | Acute myeloid leukemia | Completed | Treatment and expression study | Cytarabine, idarubicin, lenalidomide | 18–64 | Blood, bone marrow | NCT01132586 |
| 2014 | Acute myeloid leukemia | Completed | Treatment and expression study | Pacritinib | 18+ | Blood, bone marrow | NCT02323607 |
| 2017 | Chronic lymphocytic leukemia | Completed | Treatment and expression study | Cladribine, rituximab, vorinostat | 18+ | Blood, bone marrow | NCT00764517 |
| 2013 | Chronic lymphocytic leukemia | Completed | Treatment and expression study | Bendamustine, rituximab | 18+ | Blood, bone marrow | NCT01832922 |
| 2009 | Chronic myelomonocytic leukemia | Completed | Treatment and expression study | Azacitidine, lintuzumab | 18+ | Blood, bone marrow | NCT00997243 |
| 2012 | Multiple hematologic malignanices | Completed | Treatment and expression study | Fludarabine phosphate, methoxyamine | 18+ | Blood, bone marrow | NCT01658319 |
| 2010 | Multiple hematologic malignanices | Completed | Treatment and expression study | Azacitidine, bortezomib | 18+ | Blood | NCT01129180 |
| 2015 | Acute myeloid leukemia | Active | Treatment and expression study | 1–21 | Blood, bone marrow | NCT02642965 | |
| 2012 | T-cell leukemia/lymphoma | Recruiting | Expression study | 18+ | Blood, bone marrow, skin tissue, tumor tissue, urine | NCT01676805 | |
| 2018 | Acute myeloid leukemia | Recruiting | Treatment and expression study | Daratumumab, donor lymphocytes | All | Blood, bone marrow | NCT03537599 |
| 2011 | Multiple hematologic malignanices | Completed | Treatment and expression study | Histone deacetylase inhibitor 4SC-202 | 18+ | Blood, bone marrow | NCT01344707 |